Kristian Humer - 09 Dec 2025 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Reporting relationship: Chief Financial Officer
Issuer ticker: FDMT
Reported as of: 09 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Dec 2025, 16:18:02 UTC
Prior SEC filing: 17 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Scott Bizily as Attorney-in-Fact for Kristian Humer

Key filing fact

Kristian Humer filed Form 4 for 4D Molecular Therapeutics, Inc. (FDMT) on 11 Dec 2025.

Key facts

This page summarizes Kristian Humer's Form 4 filing for 4D Molecular Therapeutics, Inc. (FDMT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Dec 2025, 16:18.

Change

Previous filing in this sequence was filed on 17 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001872280 Primary reporting owner

Humer Kristian

Relationship: Chief Financial Officer
Address: C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE
Signature: /s/ Scott Bizily as Attorney-in-Fact for Kristian Humer
Signature date: 11 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FDMT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +480,000
Change %
Price: $0.000000
Shares after: 480,000
Date: 09 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 480,000
Exercise price: $10.51
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the stock option vest on the first anniversary measured from November 17, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.